Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Am J Hematol. 2019 Apr;94(4):E90-E93. doi: 10.1002/ajh.25387. Epub 2019 Jan 8.
Am J Hematol. 2019.
PMID: 30592080
Free article.
Clinical Trial.
No abstract available.
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
Moliterno DJ; TENACITY Steering Committee and Investigators.
Moliterno DJ, et al.
Catheter Cardiovasc Interv. 2011 Jun 1;77(7):1001-9. doi: 10.1002/ccd.22876. Epub 2011 Jan 11.
Catheter Cardiovasc Interv. 2011.
PMID: 21598351
Clinical Trial.
Item in Clipboard
Cite
Cite